SEQUELA AND RISKS OF COVID-19 VACCINES
DOI:
https://doi.org/10.53555/nnmhs.v8i6.1300Keywords:
COVID -19, risks,, sequela .nursing, vaccinesAbstract
Billions of people around the world are vaccinated with the COVI19 vaccine. The virus that claimed the lives of millions of people of different races and ages, and the antiviral vaccine is an important means of preventing and protecting against infection for a period of time. Data of the present study which conducted in Basrah city southern of Iraq , showed that male 46% of the vaccinated participants were male more than female ,59% of them between 23 -30 years of age,72% vaccinated with Pfizer and most of them showed symptom for post vaccination after 1-6 day. Fever significantly rise with Pfizer vaccine, post vaccinated complication correlated with persons have chronic diseases , post complications symptom correlate with age and period, ,sex and work are not significant .
References
Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (December 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. 7749790. PMID 33341119.
Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (5 March 2020). "Coronavirus (COVID-19) Vaccinations – Statistics and Research". Our World in Data. Retrieved 7 February 2021.
Mullard A (November 2020). "How COVID vaccines are being divvied up around the world". Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID 227246811.
"Kazakhstan rolls out its own COVID-19 vaccine". Reuters. 27 April 2021. Retrieved 2 July 2021.
"FarsNews Agency Iran Licenses Emergency Injection of Home-Made Anti-Coronavirus Vaccine". Fars News Agency. 14 June 2021. Retrieved 25 August 2021.
"VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Retrieved 11 January 2021.
oronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 4 December 2021. Public Domain This article incorporates text from this source, which is in the public domain.
"Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020.
641.2004.01272.x. PMID 15479434. S2CID 154670.
"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.
PT. Bio Farma (10 August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
Chen W, Al Kaabi N (18 July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Retrieved 15 August 2020.
Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Retrieved 11 April 2021.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Journal of Advance Research in Medical & Health Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Terms & Condition
Submission -
Author can submit the manuscript through our online submission process or email us at the designated email id in contact details.
The other mode of submission not accepted than online and email.
Before submission please read the submission guidelines.
NN Publication accepts only article submitted in pdf/doc/docx/rtf file format. Another format except given file formats will no be considered .
Author will be responsible for the error mistakes in the submission files. The minor changes can be done without any cost after publication. But for major changes NN Publication may charges you the editing charges.
Publication (Online) -
The online publication is scheduled on last date of every month, but it can be delayed by 24 to 48 hours due to editorial process if huge number of articles comes to publish in single issue.
Automatic notificatation email will be sent to the all users on publication of an issue, so its author’s duty to check their email inbox or SPAM folder to get this notification.
After publication of article author can not withdraw their article.
If editor’s found any issue after publication of article then the NN Publication have the authority to remove the article from online website.
No refund will be provided after online publication of article.
Publication (Print) -
The print copy publication are sent as per the author’s request after 2 weeks of online publication of that issue.
NN Publication will ship the article by India Post and provide the consignment number on dispatch of print copy.
NN Publication follows all the guidelines of delivery provided by IndiaPost and hence not responsible for delay in delivery due to any kind of reasons.
Refund of hard copy will not be provided after dispatch or print of the journal.
NN Publication will be responsible for raise a complain if there is any issue occurs in delivery, but still will not be responsible for providing the refund.
NN Publication will be responsible to resend the print copy only and only if the print copy is lost or print copy is damaged in delivery / or there is delay more than 6 months.
According to India Post the delivery should be completed with in 1-3 weeks after dispatch of articles.
Privacy Policy-
NN Publicationl uses the email ids of authors and editors and readers for sending editorial or publication notification only, we do not reveal or sell the email ids to any other website or company.
